Pregabalin Capsule
Product Images NDC 80425-0028

15 FDA label images from Advanced Rx Of Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of pregabalin, showing a 3D skeletal formula with functional groups including NH2 and CO2H, representing its molecular arrangement.*
FDA Label Image

Fig 1 (Figure 1)

Fig 1 (Figure 1)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, compared to placebo. The graph shows trends of patient improvement associated with different dosages over a range of pain improvement percentages.*
FDA Label Image

Fig 2 (Figure 2)

Fig 2 (Figure 2)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The vertical axis shows percentage of patients improved, and the horizontal axis shows percentage improvement in pain, with two distinct curves representing the treatment and placebo groups.*
FDA Label Image

Fig 3 (Figure 3)

Fig 3 (Figure 3)
A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, with lines indicating improvement trends for each dosage.*
FDA Label Image

Fig 4 (Figure 4)

Fig 4 (Figure 4)
A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three distinct curves indicating varying effectiveness of the different doses versus placebo.*
FDA Label Image

Fig 5 (Figure 5)

Fig 5 (Figure 5)
A line graph displaying percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The Pregabalin lines show a higher percent of patients improved compared to placebo across different pain improvement percentages.*
FDA Label Image

Fig 6 (Figure 6)

Fig 6 (Figure 6)
A bar chart showing responder rates (%) from two clinical studies labeled Study E1 and Study E3. The x-axis shows different dosing groups including placebo and various daily dosages. The y-axis shows responder rates ranging from 0% to 60%. The chart compares response rates across doses, highlighting statistically significant increases versus placebo.*
FDA Label Image

Fig 7 (Figure 7)

Fig 7 (Figure 7)
A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day. The graph contains four study groups labeled E1 BD, E2 TID, E3 BD, and E3 TID, with dose values ranging from 0 to 600 mg/day. Significant p-values (≤ 0.0001 and 0.0007) are marked for specific data points, illustrating the dose-response relationship in seizure reduction.*
FDA Label Image

Fig 9 (Figure 9)

Fig 9 (Figure 9)
A line graph showing the percent of patients improved relative to the percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 800 mg daily doses, compared to placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved. Multiple dose levels of Pregabalin demonstrate higher percentages of patient improvement than placebo across the range.*
FDA Label Image

Fig 10 (Figure 10)

Fig 10 (Figure 10)
A Kaplan-Meier survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis shows time in days. The solid line represents Pregabalin, and the dashed line represents the placebo group.*
FDA Label Image

Fig 11 (Figure 11)

Fig 11 (Figure 11)
A line graph showing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF for Pregabalin capsules 75 mg and placebo. The x-axis represents percent improvement from baseline to week 12, ranging from 0 to 100%, and the y-axis represents the percent of subjects improved, also from 0 to 100%. The graph features two lines: a solid line for Pregabalin and a dotted line for placebo, illustrating higher improvement percentages in the Pregabalin group compared to placebo.*
FDA Label Image

Fig. 12 (Figure 12)

Fig. 12 (Figure 12)
A line graph depicting the percent of subjects improved from baseline to Week 16 BOCF. The X-axis shows percentages from greater than 0 to 100, and the Y-axis shows percent of subjects improved from 0 to 100. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, illustrating the comparative improvement percentages over the range.*
FDA Label Image

Label 1 (Label 1)

Label 1 (Label 1)
Pregabalin 75 mg capsule packaging label from Advanced Rx of Tennessee, LLC. The label includes the product name, strength, manufacturer, storage instructions, and a barcode. It indicates a package size of 60 capsules with expiration date 6/30/2024 and controlled substance schedule C-V.*
FDA Label Image

Label 2 (Label 2)

Label 2 (Label 2)
The packaging label for Pregabalin 75 mg capsule by Advanced Rx of Tennessee, LLC. The label includes the product name, strength, form, manufacturer, and NDC number 80425-0028. It also contains storage instructions, lot number 90PRE75624, expiration date 6/30/2024, and a comparison reference to LYRICA. The label has a DEA schedule C-V marking and a barcode with additional manufacturing details.*
FDA Label Image

Label 3 (Pregabalin 75mg 80425 0028 03)

Label 3 (Pregabalin 75mg 80425 0028 03)
Pregabalin 75 mg capsule packaging label from Advanced Rx of Tennessee, LLC. The label includes storage instructions to keep the product at 20-25°C (68-77°F). It notes the quantity (#30 capsules) and references comparing it to Lyrica, including NDC numbers and placeholder lot and expiration details (expires 11/30/2025). Manufacturer information for Sciegen Pharmaceuticals is also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.